Direkt zum Inhalt
  1. Publizieren |
  2. Suche |
  3. Browsen |
  4. Neuzugänge rss |
  5. Open Access |
  6. Rechtsfragen |
  7. EnglishCookie löschen - von nun an wird die Spracheinstellung Ihres Browsers verwendet.

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

Hoffmann, Katrin ; Ganten, Tom ; Gotthardt, Daniel ; Radeleff, Boris ; Settmacher, Utz ; Kollmar, Otto ; Nadalin, Silvio ; Karapanagiotou-Schenkel, Irini ; von Kalle, Christof ; Jäger, Dirk ; Büchler, Markus W. ; Schemmer, Peter

In: BMC Cancer, 15 (2015), Nr. 392. S. 1-11. ISSN 1471-2407

[thumbnail of 12885_2015_Article_1373.pdf]
Vorschau
PDF, Englisch
Download (952kB) | Lizenz: Creative Commons LizenzvertragImpact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial von Hoffmann, Katrin ; Ganten, Tom ; Gotthardt, Daniel ; Radeleff, Boris ; Settmacher, Utz ; Kollmar, Otto ; Nadalin, Silvio ; Karapanagiotou-Schenkel, Irini ; von Kalle, Christof ; Jäger, Dirk ; Büchler, Markus W. ; Schemmer, Peter steht unter einer Creative Commons Namensnennung 3.0 Deutschland

Zitieren von Dokumenten: Bitte verwenden Sie für Zitate nicht die URL in der Adresszeile Ihres Webbrowsers, sondern entweder die angegebene DOI, URN oder die persistente URL, deren langfristige Verfügbarkeit wir garantieren. [mehr ...]

Abstract

Background: Liver Transplantation (LT) is treatment of choice for patients with hepatocellular carcinoma (HCC) within MILAN Criteria. Tumour progression and subsequent dropout from waiting list have significant impact on the survival. Transarterial chemoembolization (TACE) controls tumour growth in the treated HCC nodule, however, the risk of tumour development in the untreated liver is increased by simultaneous release of neo-angiogenic factors. Due to its anti-angiogenic effects, Sorafenib delays the progression of HCC. Aim of this study was to determine whether combination of TACE and Sorafenib improves tumour control in HCC patients on waiting list for LT. Methods: Fifty patients were randomly assigned on a 1:1 ratio in double-blinded fashion at four centers in Germany and treated with TACE plus either Sorafenib (n = 24) or placebo (n = 26). The end of treatment was development of progressive disease according to mRECIST criteria or LT. The primary endpoint of the trial was the Time-to-Progression (TTP). Other efficacy endpoints were Tumour Response, Progression-free Survival (PFS), and Time-to-LT (TTLT). Results: The median time of treatment was 125 days with Sorafenib and 171 days with the placebo. Fourteen patients (seven from each group) developed tumour progression during the course of the study period. The Hazard Ratio of TTP was 1.106 (95% CI: 0.387, 3.162). The results of the Objective Response Rate, Disease Control Rate, PFS, and TTLT were comparable in both groups. The incidence of AEs was comparable in the placebo group (n = 23, 92%) and in the Sorafenib group (n = 23, 96%). Twelve patients (50%) on Sorafenib and four patients (16%) on placebo experienced severe treatment-related AEs. Conclusion: The TTP is similar after neo-adjuvant treatment with TACE and Sorafenib before LT compared to TACE and placebo. The Tumour Response, PFS, and TTLT were comparable. The safety profile of the Sorafenib group was similar to that of the placebo group. Trial registration: ISRCTN24081794

Dokumententyp: Artikel
Titel der Zeitschrift: BMC Cancer
Band: 15
Nummer: 392
Verlag: BioMed Central
Ort der Veröffentlichung: London
Erstellungsdatum: 08 Jan. 2016 13:25
Erscheinungsjahr: 2015
ISSN: 1471-2407
Seitenbereich: S. 1-11
Institute/Einrichtungen: Medizinische Fakultät Heidelberg und Uniklinikum > Medizinische Universitäts-Klinik und Poliklinik
Medizinische Fakultät Heidelberg und Uniklinikum > Chirurgische Universitätsklinik
Medizinische Fakultät Heidelberg und Uniklinikum > Radiologische Universitätsklinik
DDC-Sachgruppe: 610 Medizin
Leitlinien | Häufige Fragen | Kontakt | Impressum |
OA-LogoDINI-Zertifikat 2013Logo der Open-Archives-Initiative